Unicycive Therapeutics, Inc. Logo

Unicycive Therapeutics, Inc.

A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.

UNCY | US

Overview

Corporate Details

ISIN(s):
US90460M2044 (+1 more)
LEI:
Country:
United States of America
Address:
4300 EL CAMINO REAL, SUITE 210, 94022 LOS ALTOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2016, dedicated to developing and commercializing novel treatments for kidney diseases. The company focuses on identifying overlooked opportunities and addressing unmet medical needs for patients with renal conditions. Its lead investigational treatment is oxylanthanum carbonate (OLC). Unicycive utilizes an agile development process, leveraging its team's expertise to efficiently advance promising technologies into commercial therapies for patients in need.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Unicycive Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Unicycive Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Unicycive Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Inventage Lab Inc. Logo
Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.
South Korea
389470
Inventiva S.A. Logo
Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.
United States of America
IVA
Invivyd, Inc. Logo
Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.
United States of America
IVVD
IO Biotech, Inc. Logo
Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.
United States of America
IOBT
IONIS PHARMACEUTICALS INC Logo
A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.
United States of America
IONS
IOVANCE BIOTHERAPEUTICS, INC. Logo
Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.
United States of America
IOVA
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France
IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden
IRLAB
IRONWOOD PHARMACEUTICALS INC Logo
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America
IRWD
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea
086890

Talk to a Data Expert

Have a question? We'll get back to you promptly.